ASLAN Pharmaceuticals (NASDAQ:ASLN) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

Separately, Piper Sandler reissued an overweight rating and set a $10.00 target price (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Up 10.0 %

Shares of NASDAQ ASLN opened at $0.54 on Monday. The firm has a market cap of $8.83 million, a PE ratio of -0.20 and a beta of 1.45. ASLAN Pharmaceuticals has a 12-month low of $0.39 and a 12-month high of $4.69. The company’s fifty day simple moving average is $0.61 and its 200 day simple moving average is $0.76.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC raised its holdings in ASLAN Pharmaceuticals by 68.2% during the third quarter. Schonfeld Strategic Advisors LLC now owns 91,500 shares of the company’s stock worth $172,000 after buying an additional 37,100 shares during the last quarter. Millennium Management LLC raised its holdings in ASLAN Pharmaceuticals by 2.8% during the second quarter. Millennium Management LLC now owns 1,613,113 shares of the company’s stock worth $804,000 after buying an additional 43,949 shares during the last quarter. Bank of America Corp DE raised its holdings in ASLAN Pharmaceuticals by 34.4% during the first quarter. Bank of America Corp DE now owns 259,722 shares of the company’s stock worth $233,000 after buying an additional 66,544 shares during the last quarter. Virtu Financial LLC raised its holdings in ASLAN Pharmaceuticals by 389.6% during the fourth quarter. Virtu Financial LLC now owns 88,106 shares of the company’s stock worth $32,000 after buying an additional 70,109 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in ASLAN Pharmaceuticals during the first quarter worth $64,000. Institutional investors and hedge funds own 58.82% of the company’s stock.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.